Open AccessEGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature
Author(s) -
Ran Zeng,
Lifeng Luo,
Xianwen Sun,
Zhiyao Bao,
Wei Du,
Ranran Dai,
Wei Tang,
Beili Gao,
Yi Xiang
Publication year - 2021
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.98
Subject(s) - trametinib , osimertinib , dabrafenib , cancer research , mek inhibitor , mutation , medicine , lung cancer , epidermal growth factor receptor , v600e , adenocarcinoma , oncology , cancer , mapk/erk pathway , kinase , biology , vemurafenib , melanoma , gene , erlotinib , genetics , metastatic melanoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom